Cargando…

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review

PURPOSE: Opioid dependence (OD) is a serious and growing clinical condition with increasing social costs that requires expanding treatment beyond opioid agonist substitution. The opioid antagonist naltrexone has displayed a remarkable association of theoretical effectiveness and poor clinical utilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mannelli, Paolo, Peindl, Kathleen S, Wu, Li-Tzy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128868/ https://www.ncbi.nlm.nih.gov/pubmed/21731898 http://dx.doi.org/10.2147/SAR.S15853

Ejemplares similares

Long-Acting Injectable Naltrexone for the Management of Patients with Opioid Dependence
por: Kjome, Kimberly L., et al.
Publicado: (2011)

Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Primary care for opioid use disorder
por: Mannelli, Paolo, et al.
Publicado: (2016)

The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose
por: Krieter, Philip, et al.
Publicado: (2019)

Naltrexone and the Treatment of Alcohol Dependence
por: Volpicelli, Joseph R., et al.
Publicado: (1994)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Naltrexone long-acting formulation in the treatment of alcohol dependence
por: Johnson, Bankole A
Publicado: (2007)

Thermosensitive biomaterial gels with chemical permeation enhancers for enhanced microneedle delivery of naltrexone for managing opioid and alcohol dependency
por: Tobin, Kevin V., et al.
Publicado: (2023)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”
por: Silverman, Bernard, et al.
Publicado: (2018)

Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
por: Wu, Li-Tzy, et al.
Publicado: (2023)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
por: Reece, Albert Stuart
Publicado: (2012)

Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia
por: Shaheed, Gurneet, et al.
Publicado: (2021)

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study
por: Micheli, Laura, et al.
Publicado: (2020)

The opioid overdose epidemic: opportunities for pharmacists
por: Wu, Li-Tzy, et al.
Publicado: (2017)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

Use of methyl-naltrexone for the treatment of opioid-induced constipation in critical care patients
por: Sawh, SB, et al.
Publicado: (2010)

Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions
por: Wu, Li-Tzy, et al.
Publicado: (2011)

Anhedonia to music and mu-opioids: Evidence from the administration of naltrexone
por: Mallik, Adiel, et al.
Publicado: (2017)

The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia
por: Jackson, Daniel, et al.
Publicado: (2021)

Pharmacological and Behavioral Treatment of Opioid Use Disorder
por: Sofuoglu, Mehmet, et al.
Publicado: (2018)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

Naltrexone as a Treatment for Heroin Dependence and its relationship with Depression
por: Kak, Insha Mehraj, et al.
Publicado: (2022)

Kratom-induced transaminitis with subsequent precipitated opioid withdrawal following naltrexone
por: Jensen, Aimee N., et al.
Publicado: (2021)

Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
por: Wu, Li-Tzy, et al.
Publicado: (2023)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data
por: John, William S., et al.
Publicado: (2022)

Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
por: Ruger, Jennifer Prah, et al.
Publicado: (2012)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review
por: Farhadian, Negin, et al.
Publicado: (2020)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice
por: Wang, Yu‐Syuan, et al.
Publicado: (2021)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
por: Toljan, Karlo, et al.
Publicado: (2018)

Effects of Naltrexone on Pain Sensitivity and Mood in Fibromyalgia: No Evidence for Endogenous Opioid Pathophysiology
por: Younger, Jarred W., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_2cqg3q1v0kspc9uahnm4c8bgli